Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Short-term Investments (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Short-term Investments for 5 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments fell 89.53% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Sep 2025, down 89.53%, and an annual FY2024 reading of $26.8 million, down 66.02% over the prior year.
  • Short-term Investments was $5.0 million for Q3 2025 at Ovid Therapeutics, down from $9.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $84.1 million in Q4 2022 and bottomed at $5.0 million in Q3 2025.
  • Average Short-term Investments over 4 years is $46.4 million, with a median of $47.5 million recorded in 2024.
  • The sharpest move saw Short-term Investments skyrocketed 89.92% in 2024, then plummeted 89.53% in 2025.
  • Year by year, Short-term Investments stood at $84.1 million in 2022, then fell by 6.35% to $78.8 million in 2023, then plummeted by 66.02% to $26.8 million in 2024, then crashed by 81.36% to $5.0 million in 2025.
  • Business Quant data shows Short-term Investments for OVID at $5.0 million in Q3 2025, $9.9 million in Q2 2025, and $21.9 million in Q1 2025.